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Neuroendocrine tumours (NETs) are often indolent malignancies that commonly present with metastatic disease in the liver.
Surgical, locoregional, and systemic treatment modalities are reviewed. A multidisciplinary approach to patient care is suggested
to ensure all therapeutic options explored.
1.Introduction
Neuroendocrine tumours (NETs) are uncommon tumours
that can arise anywhere within the body, but predominantly
from the gastroenteropancreatic tract. Recent epidemiologi-
cal evidence suggest that the incidence of all NETs is approxi-
mately3–5per100,000populationperyearwithaprevalence
of 35 per 100,000 population becauseof slow tumour growth
[1, 2]. Though most NETs are nonfunctional, others secrete
peptide hormones that can cause clinical syndromes, like
ﬂushing, diarrhoea, bronchospasm and palpitations seen
with carcinoid syndrome. The majority of these tumours are
indolent, slow growing malignancies, commonly presenting
with metastatic disease. The most common site of distant
metastases is the liver. Consequently, many therapies are
focused at treating the primary and also the metastatic
disease in the liver. Due to the indolent nature of most of
thesetumours,the5-yearsurvivalofpatients withmetastatic
disease at presentation is approximately 50%. There may
have been some improvement in survival from medical and
surgical therapies. New molecular-targeted therapies and an
aggressive surgical approach to resection of primary and
secondary tumours show beneﬁt.
This paper focuses on management of liver metastases
of NETs and covers both surgery, locoregional, and systemic
therapy. In general, local therapies to the liver should be
considered ﬁrst if disease is conﬁned to the liver. This allows
systemic therapies to be given at a later stage if there is
extrahepatic spread. Results for liver-directed and systemic
therapy of neuroendocrine tumour liver metastases are sum-
marised in Tables 1 and 2,r e s p e c t i v e l y .
2. Liver-directedTherapies
Consensus guidance recommends surgery for liver metas-
tases in well-diﬀerentiated NETs if complete resection or
debulking of <90% tumour load is feasible [45]. However,
intended curative surgery is only possible in less than 10%
of patients who are diagnosed with hepatic metastases at
presentation [3, 46–49]. The distribution of liver metas-
tases aﬀects survival; solitary metastases, isolated metastatic
bulk with smaller accompanying deposits, and disseminated
metastatic spread have 5-year survival rates of 100%, 84%,
and 51%, respectively [50].
An aggressive surgical approach to resecting liver metas-
tases is supported by signiﬁcantly improved actuarial sur-
vival in series compared to nonrandomised controls [3–
5]. A number of diﬀerent surgical approaches are available
depending on the distribution of metastases. If primarily
unilobar metastases are present, a one-step approach can be
adopted. In these cases, resection of the primary plus liver
resection can be performed. A two-step surgical approach
to bilobar metastases from luminal NETs with resection of
the primary, limited resection of left liver lobe metastases,
and right portal vein ligation followed by right hepatectomy
hasbeenproposed[6].Overallsurvivalanddisease-freerates
at 5 years were 94% and 50% with this approach. Other2 International Journal of Hepatology
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series report a range of overall survival and disease-free rates
[7–9, 51]. A signiﬁcant improvement in 3-year survival for
surgical resection over medical treatment or embolisation
has been demonstrated in a study limited by bias. [10]. The
completeness of resection, in particular resection margin
involvement, is thought to be more important than the
number, localization, and size of liver metastases [7, 52, 53].
Histological grade and extrahepatic disease are predictive of
overall survival [54, 55]. Disease has been shown to recur in
78–94% of patients at 5 years [3, 8, 11].
After surgery, patients with functioning tumours have
prolonged partial or complete symptomatic response rates
that can contribute to improved quality of life [11, 56, 57].
Patients with carcinoid tumours have reduced biomarkers
(e.g., Chromogranin A and urinary 5-HIAA) after surgery
that correlate with symptom relief and disease control [3,
58]. Some rarer functioning syndromes, like those related
to PTHrP or VIP secretion, can be improved by debulking
surgery [59].
There is no evidence from randomised clinical trials sup-
porting liver surgery, either for curative resection or for
debulking in nonresectable disease, over other treatment
modalities. Liver surgery only achieved signiﬁcance in im-
proving survival in univariate but not multivariate analysis
[60–62]. Neoadjuvant strategies for downsizing liver metas-
tases or adjuvant chemotherapy following hepatic resection
have not yet been subject to controlled clinical trials [63–65].
2.1. Surgery to Primary Tumour in Metastatic NETs. Recent
guidelines recommend resection of the primary tumour and
mesenteric lymph nodes in jejunum/ileum NETs [66–68].
Tumour mass reduction or debulking of primary jejunal and
ileal NETs reduces the possibility of bowel ischaemia and
obstruction from tumour and mesenteric lymph nodes mass
eﬀect even in the context of liver metastases. Resection of
the primary tumour has been shown to be an independent
positive predictor of survival (P = 0.015) and associated
withasigniﬁcantlylongersurvivalthannoresection(median
survival 7.4 versus 4.0 years; P<0.01) [62, 69]. Successful
resection of mesenteric metastases and the desmoplastic
reaction around the primary site are also associated with
a signiﬁcantly longer survival. Signiﬁcant reductions in
tumour-related symptoms are also seen after primary and
mesenteric lymph node resections.
Aggressive surgery to primary tumours and resectable
liver metastases in pancreatic NETs is recommended [67,
70]. Resection of pancreatic NETs has been suggested to be
associated with signiﬁcantly improved survival compared to
those who did not undergo resection (114 months versus 35
months; P<. 0001) though signiﬁcant biases may exist in
this study [71]. This survival beneﬁt was demonstrated for
patients with localized, regional, and metastatic disease with
an adjusted odds ratio of 0.48. Independent predictors of
survivalafterresectionofpancreaticNETsincludeage,grade,
presence of distant metastases, tumour functionality, and
typeofresection[72].Currentguidelinesdonotrecommend
surgery to the primary pancreatic tumour in patients with
unresectable liver metastases [70, 73].
2.2. Transplantation. The role of orthotopic liver transplant
iscontroversialgiventhedemandfordonororgansandalack
of clear selection criteria [74]. Patients with debilitating and
poorly controlled hormonal syndromes from small intestine
or pancreatic NETs are considered for transplantation as
symptom relief is seen in 90% of patients following surgery
[12, 13, 75–78]. Five-year recurrence-free rates vary from
25–50%. Overall ﬁve-year survival rates are around 50% but
vary according to patient selection [13, 14, 79, 80]. Patients
presenting with duodenal or pancreatic NET in association
with hepatomegaly have poorer outcomes (12% versus 68%
ﬁve-year survival rates) [14]. The presence of extensive
extrahepatictumourresectedatthetimeoftransplantationis
associated with poorer median and ﬁve-year survival rates of
ten months and 30%, respectively [12]. Important selection
criteria include well-diﬀerentiated tumours, low prolifera-
tion rate (Ki-67 < 10%), and regular E-Cadherin staining
[81, 82]. The Milan criteria for transplantation include
age less than 55 years, low grade carcinoid NET, limited
metastatic disease in the liver (<50%), previously resected
tumours drained only by the portal system (pancreas and
mid gut origin NETs), and stable disease for 6 months
[83]. Combination treatment with chemotherapeutic agents,
chemoembolisation, systemic radiopeptide treatment, and
aggressive surgery for recurrence may lead to improved
survival rates [84–86].
2.3. Embolisation. NET liver metastases are highly vascular
with an arterial supply that if occluded will lead to ischaemia
and necrosis. Normal tissue is supplied from the portal
vein and preserved during embolisation of hepatic arteries.
A catheter is guided to the hepatic artery or branch and
material(gelfoampowder,microembospheres,andpolyvinyl
alcohol particles) released to occlude the vessel in bland
embolisation. In chemoembolisation, cytotoxics (like cis-
platin, mirplatin, gemcitabine, doxorubicin, streptozocin,
and 5-FU) are injected prior to arterial embolisation in order
to achieve higher concentrations and prolonged action in
necrotic tissue [87–89]. Contraindications to embolisation
include occlusion of the portal vein, severe liver dysfunction,
and presence of biliary anastomosis. Relative contraindi-
cations include tumour burden, renal impairment, and
heart disease (including carcinoid heart disease) [90, 91]. A
postembolisationsyndromemayoccurwithabdominalpain,
vomiting, fever, and rise in transaminases.
Vascular occlusion can achieve reduced hormonal symp-
toms from NET syndromes, reduced tumour burden, and
improvedsurvivalinpatientswhohavetriedmedicaltherapy
and who are not suitable for surgical resection [92–95].
Sequential hepatic artery occlusion can oﬀer prolonged
palliation for responsive patients even if performed later in
their clinical course [90, 96, 97].
Median survival rates after transarterial embolisation
(TAE) or chemoembolistaion (TACE) in patients with
liver metastases is over 3 years with progression-free sur-
vival (PFS) of around 18 months [15–18, 98–100]. Clin-
ical response rates of over 90% are seen following treat-
ment [91]. Intact primary tumour, extensive liver disease,
and bone metastases are associated with worse outcomes.International Journal of Hepatology 5
Embolisation of nonresectable liver metastases often results
in disease regression in patients with carcinoid or pancreatic
NETs [17, 19]. TACE appears to beneﬁt patients with
pancreatic NETs while TAE beneﬁts those with ileal NETs
[20]. A small randomized study of TAE versus TACE in all
liver NETs has shown no diﬀerence in time to progression
[101].
2.4. Radiofrequency Ablation (RFA). RFA of oligonodular
liver metastases (fewer than 8) of less than 5cm can result in
symptomatic response in 70–80% of patients with hormonal
syndromes for as long as 24 months [21, 63, 102, 103].
Electrical energy is delivered to tissues via a catheter, inserted
percutaneously or laparoscopically, which leads to heating
and cell death [104, 105]. Microwave RFA can reduce time
required for this procedure. RFA can play an important
role in the treatment of carcinoid metastases not suitable
for surgical resection and refractory to TAE, improving
symptom control, reducing octreotide dependence, and
slowing progression in patients [106–108]. Limitations to
using RFA include increased numbers and size of liver
metastases as well as the detrimental cooling eﬀect of blood
ﬂow from neighbouring blood vessels. Local recurrence has
been identiﬁed in 21.7% of tumours on CT scans with a
mean follow-up of 17 months. Recurrence can be predicted
by tumour type and size, ablation margin, and blood vessel
proximity [103, 109]. Median survival after starting RFA
treatment is 3.9 years [21]. Although RFA may play a
promising role in the treatment of liver metastases from
NETs, its eﬀect on survival and tumour progression needs to
beexploredinlargerstudies.Inparticular,studiesareneeded
comparing surgical resection with RFA.
2.5. Selective Internal Radiation Therapy (SIRT). Radioem-
bolisation of liver metastases can be achieved with Yttrium-
90 resin microspheres in patients with disseminated and
inoperable liver disease even if previous TAE or TACE
has taken place [22, 110]. (90Y) microspheres are injected
through a percutaneously placed hepatic artery catheter
via the femoral or brachial artery. Contraindication to
SIRT is similar to those of bland embolisation, vascular
involvement such as portal vein thrombosis, severe liver
dysfunction,andlargetumourburden.Long-termradiologic
and biological responses can be achieved with radioem-
bolisation with partial or complete response seen in 63%
[22, 23] .M e d i a ns u r v i v a lv a r i e sf r o m3 6t o7 0m o n t h s
[23, 24]. Prognostic factors include radiographic response
to treatment, tumour grade, and presence of extrahepatic
disease. Patients with hepatic tumour burden of 20–50% by
volume, well-diﬀerentiated tumour, female gender, and no
extrahepatic disease beneﬁt most from treatment [25]. There
is no randomized evidence that radiologic and symptom
response rates following SIRT are diﬀerent from those seen
with TACE and TAE.
3. Systemic Therapies
3.1. Biological Therapy. Over 70% of NETs express cell-
surface somatostatin receptors that are targeted by synthetic
somatostatin analogues. Patients with functional NETs can
derive signiﬁcant symptomatic beneﬁt from the use of
somatostatinanaloguesthatsuppressthesecretionofpeptide
hormones. Octreotide can provide symptomatic response
in up to 85% of patients and biochemical response in
up to 70% of patients within weeks of commencement
[111, 112]. Patients with NETs undergoing interventional
procedures can experience severe symptoms related to the
release of vasoactive hormones, like serotonin, that can cause
a carcinoid crisis with bronchospasm, tachycardia, and labile
blood pressure. This can be ameliorated through the use of
octreotide infusions before, during, and after interventional
procedures.
Some groups have reported an antiproliferative property
of somatostatin analogues [26, 27, 112, 113]. Octreotide
LAR has been found to signiﬁcantly lengthen the time to
tumour progression compared to placebo injections (14.3
versus 6 months resp.) [28]. The beneﬁt was seen in both
functionally active and inactive tumours. Patients with low
hepatic tumour load and resected primary tumour beneﬁted
the most from treatment with octreotide LAR. Overall,
survival was not an endpoint of this study, consequently;
survival beneﬁt from the use of somatostatin analogues has
not been conﬁrmed.
Interferon alpha 3–5 megaunits 3–5 times per week have
been used with some symptomatic response, but no clear
reduction in tumour size or survival beneﬁt [29–31, 114,
115]. Interferon alpha should be considered as second-line
biological therapy after somatostatin analogues.
3.2. Chemotherapy. Systemic chemotherapy has a role in the
treatment of pancreatic and high grade NETs. Patient selec-
tion and individualized treatment are required to minimize
toxicity, maximize response, and improve overall quality of
life. The degree of diﬀerentiation and tumour grade of NETs
can guide management [116, 117]. Poorly diﬀerentiated and
high-proliferative tumours (from histological grading like
Ki-67 and mitotic index) behave more aggressively but are
more sensitive to cytotoxic therapy than well-diﬀerentiated
andlow-proliferativetumours(Ki-67<10%)[33].Objective
response to chemotherapy varies between 25–78% with
progression-free periods between 4–22 months [32, 34,
37, 118–124]. Therefore, it is essential to ensure that
chemotherapyisoﬀeredtopatientswhoarelikelytorespond;
those with pancreatic NETs, aggressive phenotypes, and
high proliferation rates [125]. Biochemical and radiological
progression in asymptomatic patients identiﬁes those with
rapidly progressive disease and an aggressive phenotype
[67]. Response to cytotoxic therapy can be established from
radiological-quantiﬁed reduction in tumour size, improved
biochemical markers as well as improvements in quality of
life as measured by health questionnaires [126–128].
Single-agent chemotherapy is seldom used because of
limited response rates, toxicity, and poor survival rates.
Newer agents like paclitaxel, temozolomide, topotecan, and
gemcitabine are not markedly better than older agents
like streptozocin, dacarbazine, 5 ﬂourouracil, and doxoru-
bicin when used as monotherapy [121, 126, 129–135]. In
patients with pancreatic NET, combination chemotherapy6 International Journal of Hepatology
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and 5FU in terms of response rates, time to progression,
and overall survival [32, 136, 137]. Response rates from
streptozocin and doxorubicin combination treatment vary
between 30–70% [33–35, 138]. Recently, a retrospective
analysis of capecitabine and temozolomide combination
chemotherapy has demonstrated good response rates, supe-
rior to traditional streptozocin-based chemotherapy [36].
In 30 patients treated with capecitabine and temozolomide,
response rates of 70%, progression-free survival of 18
months and overall survival of 92% at 2 years were observed.
However, streptozocin-based therapy remains the standard
chemotherapy regime for pancreatic NETs given the lack
of data from randomised trials demonstrating beneﬁt from
other regimes [36, 116, 123, 139, 140]. Poorly diﬀerentiated
oranaplasticNETsrespondtoacombinationofcisplatinand
etoposide, a regime used in small cell lung cancer [37, 118–
120]. Despite chemotherapy, the prognosis remains poor in
this group with a 2-year survival between 20–30%.
3.3.Molecular-TargetedTherapies. Novel systemic agents tar-
get the molecular mechanisms that are implicated in the
pathogenesis of NETs [141, 142].
Sunitinib, a multitargeted tyrosine kinase inhibitor, has
activity against a range of molecular targets, including VEGF
receptors and platelet-derived growth factor receptors, and
has been shown to have antitumour activity in pancreatic
NETs [143]. Median PFS is signiﬁcantly longer in patients
treated with sunitinib over placebo (11.4 versus 5.5 months)
[38]. Objective response rates and overall survival are also
improved with sunitinib treatment. Frequent adverse events
encountered include diarrhoea, nausea, vomiting, asthenia,
and fatigue.
Everolimus, an oral inhibitor of mammalian target of
rapamycin (mTOR), has activity against pancreatic NET
tumours through a mechanism of cellular apoptosis and
antiangiogenesis [144, 145]. Median PFS is signiﬁcantly
longer in those treated with everolimus over placebo (11
versus 4.6 months) [39]. Severe adverse events like hyper-
glycaemia and anaemia were rare, with stomatitis, diarrhoea,
and fatigue are more commonly seen.
Vascular endothelial growth factor (VEGF) is overex-
pressed in NETs and targeted by the ligand monoclonal
antibody Bevacizumab [40, 146, 147]. There are reports of
clinical beneﬁt when combined with existing chemotherapy
treatments [148, 149].
3.4.PeptideReceptorRadionuclideTherapy(PRRT). Somato-
statin receptors subtype 2 are expressed in the majority of
NETs and conﬁrmed through uptake in octreotide scintig-
raphy or somatostatin-based PET imaging [150–152]. Beta-
emitting 90 Y- and 177 Lu-labeled somatostatin analogues
have been studied in patients with metastatic and inoperable
disease [41, 42, 153–156]. The majority of patients developInternational Journal of Hepatology 7
stable disease with the average time to progression of 40
months from commencing therapy. Partial and complete
objective responses are seen in up to 30% of patients with
median PFS of over 2 years [43, 157]. From diagnosis, there
is a survival beneﬁt of 40–72 months compared to histor-
ical controls [44]. Predictive factors include high tumour
uptake on scintigraphy and limited liver metastases. Adverse
events include bone marrow and liver toxicity as well as
radiation-induced lose of renal function and gastrointestinal
disturbance from the use of renoprotective agents [158,
159]. The addition of radiosensitisers like gemcitabine and
capecitabine to PPRT may improve clinical outcomes [160,
161].Alpha-emittingisotopes, suchasactinum-225(225Ac),
haveahighercytotoxicactivitythanbetaemittersandmaybe
used in PRRT [162].
MIBG scans are also used to identify patients with
metastatic NETs. 131 I-MIBG therapy is associated with
signiﬁcantly improved 5-year survival rates of 85% (non-
randomized studies) as well as marked symptomatic and
hormonal improvement [163–165]. Symptomatic response
predicts improved survival.
4. Conclusion
There are a number of treatment modalities available in
the management of neuroendocrine tumour liver metastases
with a treatment algorithm outlined in Figure 1.P r o a c t i v e
surgical resection, with curative intent or for debulking
(cytoreduction), has been shown to improve outcomes and
should be pursued initially. In patients with more advanced
disease or not amenable to surgical resection, locoregional
therapies, like embolisation and SIRT, oﬀer improved out-
comesandmaydownstagedisease.Newersystemictherapies,
in particular PRRT and molecular targeted therapies, can
play a role in patients with extrahepatic and progressive
disease. Although there is a lack of robust evidence-based
data in the management of patients with metastatic NETs,
the future appears more positive with the range of treatment
options available. An individualized approach to patient care
is needed given the breadth of symptoms and disease, the
lack of a validated treatment pathway as well as the indolent
nature of NETs. Patient care should be managed under
the auspices of a multidisciplinary team to ensure that all
treatment options are explored both at diagnosis and follow-
up.
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